Filing Flows

Filing Flows › Bolt Biotherapeutics (BOLT) › Who owns the stock

Who owns Bolt Biotherapeutics (BOLT) stock

22 funds reported Bolt Biotherapeutics (BOLT) shares in their latest 13F filings, worth $2.2M in all. The largest holder is Sofinnova Investments ($530K). Last quarter 7 funds added to their stakes and 7 cut them.

Largest holders of BOLT (13F)Largest holders of BOLT (13F)Sofinnova Investments$530KRenaissance Technologies LLC$380KVivo Capital, LLC$279KCitadel Advisors LLC$219KBoard of Trustees of The Leland S…$139KPfizer$134KLynx1 Capital Management LP$119KNano CAP New Millennium Growth Fu…$106KGeode Capital Management, LLC$74KShay Capital LLC$59K

Largest holders (13F)

FundSharesValueChangeQuarter
Sofinnova Investments137,721$530Kunchanged2026-06-30
Renaissance Technologies LLC98,625$380Kincrease2026-06-30
Vivo Capital, LLC72,414$279Kunchanged2026-06-30
Citadel Advisors LLC56,903$219Kincrease2026-06-30
Board of Trustees of The Leland Stanford Junior University35,977$139Kunchanged2026-06-30
Pfizer31,305$134Kunchanged2026-06-30
Lynx1 Capital Management LP30,800$119Kunchanged2026-06-30
Nano CAP New Millennium Growth Fund L P27,500$106Kunchanged2026-06-30
Geode Capital Management, LLC19,119$74Kdecrease2026-06-30
Shay Capital LLC15,438$59Kincrease2026-06-30
Vanguard Group10,179$56Kdecrease2025-12-31
BlackRock9,711$37Kunchanged2026-06-30
Vanguard Capital Management LLC7,060$27Kunchanged2026-06-30
Nan Fung Group Holdings5,000$19Kdecrease2026-06-30
Morgan Stanley3,145$12Kdecrease2026-06-30

Bolt Biotherapeutics' latest quarter

Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most BOLT stock?

By the latest 13F filings: Sofinnova Investments ($530K); Renaissance Technologies LLC ($380K); Vivo Capital, LLC ($279K); Citadel Advisors LLC ($219K); Board of Trustees of The Leland Stanford Junior University ($139K).

What is the short interest in BOLT?

15,751 shares were sold short at the 2026-10-15 settlement, -38.8% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.